Medications

The CONCLUDE trial has demonstrated similar overall rates of symptomatic hypoglycemia among type 2 diabetes patients treated with insulin degludec U200 or insulin glargine U300.

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

Imeglimin, an agent that improves mitochondrial function, has demonstrated potential as a novel treatment option for Japanese patients with type 2 diabetes in the phase III TIMES 1 and TIMES 3 trials.

John McMurray talks about the results of the DAPA-HF trial, discussing whether the benefits of dapagliflozin for patients with heart failure could be extended to other SGLT2 inhibitors, and the next steps for research (3:29).

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.

Upfront combination therapy with vildagliptin and metformin is more durable than metformin alone, and appears to have a legacy effect, report the VERIFY investigators.

The addition of dapagliflozin to standard treatment may be beneficial for patients with established heart failure and reduced ejection fraction, indicate findings from the DAPA-HF trial.

A comparison of CANVAS and CANVAS-R fails to detect any potential explanation for the increased fracture risk seen with canagliflozin versus placebo in the former trial.

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.

The recent postmarketing data on Fournier gangrene in people taking sodium-glucose cotransporter 2 inhibitors has increased concerns about this very rare but potentially fatal side effect. medwireNews talks to primary care diabetes specialist Kevin Fernando about how the findings affect risk–benefit considerations.

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.